Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | PTGIR | P43119 | 10/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20335266 | 1.00 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3PTGIR | |
| SCHEMBL2375379 | 1.00 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3PTGIR | |
| SCHEMBL13408415 | 0.87 | NR1H2 (0.46) | NR1H2 | |
| SCHEMBL26999335 | 0.86 | LMNA (0.39) | CHRM2CHRM1CHRM3CTSSCTSK | |
| SCHEMBL20129230 | 0.86 | LMNA (0.35) | NR1H2CHRM2CHRM1CHRM3CTSS | |
| SCHEMBL6523531 | 0.85 | PLG (0.38) | NR1H2CHRM2CHRM1CHRM3PTGIR | |
| SCHEMBL6525510 | 0.85 | PLG (0.38) | NR1H2CHRM2CHRM1CHRM3PTGIR | |
| SCHEMBL22565736 | 0.85 | RBP4 (0.34) | NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL13867703 | 0.84 | NR1H2 (0.39) | NR1H2 | |
| SCHEMBL13867702 | 0.84 | NR1H2 (0.39) | NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50267-E1 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20250009693-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20230404954-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2023-12-21 | — | — | US | disclosed |
| EP-3884934-B1 | PHARMACEUTICAL COMPOSITION COMPRISING: 2-(((1R,4R)-4-(((4-CHLOROPHENYL)(PHENYL)CARBAMOYLOXY)METHYL)CYCLOHEXYL)METHOXY)ACETIC ACID | ARENA PHARM INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230121825-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-3884934-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-2857015-B1 | Modulators of the prostacyclin (PG12) receptor useful for the treatment of disorders related thereto | ARENA PHARM INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3342767-B1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20200392123-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200385357-A1 | SUBSTITUTED PYRIDAZINES AND 1,2,4-TRIAZINES AS PROSTACYCLIN RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-9012478-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| EP-2857015-A1 | Modulators of the prostacyclin (PG12) receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8940891-B2 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8895776-B2 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2280696-B1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20140171469-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20130217706-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20110245251-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110224262-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110053958-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053958-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | NR1H2 80/4885CHRM2 1760/4885CHRM1 1763/4885 |
| US-20130217706-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER2 | NR1H2 298/4885CHRM2 615/4885CHRM1 1074/4885 |
| US-20230121825-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PLOD3 | NR1H2 107/4885CHRM2 1877/4885CHRM1 1854/4885 |
| US-20110224262-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | NR1H2 302/4885CHRM2 2213/4885CHRM1 1661/4885 |
| US-20140171469-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | NR1H2 302/4885CHRM2 2213/4885CHRM1 1661/4885 |
| US-20110245251-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | NR1H2 162/4885CHRM2 1327/4885CHRM1 953/4885 |
| US-20250009693-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | NR1H2 80/4885CHRM2 1756/4885CHRM1 1765/4885 |
| US-20200392123-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER1 | NR1H2 302/4885CHRM2 2213/4885CHRM1 1661/4885 |
| US-20200385357-A1 | SUBSTITUTED PYRIDAZINES AND 1,2,4-TRIAZINES AS PROSTACYCLIN RECEPTOR MODULATORS | PTGIR, PTGIS, TBXA2R | NR1H2 169/4885CHRM2 807/4885CHRM1 599/4885 |
| US-20230404954-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | NR1H2 80/4885CHRM2 1760/4885CHRM1 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.